As part of the three-year agreement, AMRI gains access to Multispan's differentiated GPCR cell lines, assay capabilities and expertise. Multispan will offer customers AMRI's global integrated drug discovery services, including high-throughput screening (HTS) and discovery medicinal chemistry.
The alliance aims to increase success in GPCR drug discovery, and is an example of partnerships AMRI is creating to combine validated assays and technologies with its HTS and analytic informatics.
"We are excited to be entering into this collaboration with Multispan as we implement our new U.S. integrated drug discovery center located on the Buffalo Niagara Medical Campus," said Rory Curtis, Ph.D., vice president, Discovery Biology and Pharmacology, and site h-ead of AMRI Buffalo. "As a biotechnology company that exclusively focuses on drug discovery research targeting GPCRs, Multispan has an impressive collection of human GPCR clones and GPCR-expressing cell lines for HTS, which will be beneficial to AMRI's integrated drug discovery efforts."
"We are excited to bring our GPCR capabilities and services to AMRI's customers through this strategic alliance," added Helena Mancebo, chief executive officer of Multispan. "In addition, we are eager for our customers to have access to the leading-edge capabilities for drug discovery that AMRI's new center in Buffalo offers across biology and medicinal chemistry."
